A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Prior treatment

• Participant is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged to be scientifically or medically incompatible with this study.
• Have any unresolved toxicity of Grade ≥2 from previous anticancer treatment, except for Grade 2 alopecia or skin pigmentation. Participants with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the Investigator and Sponsor.
• Is unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal absorption of zipalertinib (eg, inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection).
• History of another primary malignancy ≤2 years prior to the date of first dose of study treatment unless at least one of the following criteria are met:
  • Adequately treated basal or squamous cell carcinoma of the skin
  • Cancer in situ of the breast or cervix
  • Participants with previously treated malignancy if all treatment for that malignancy was completed at least 2 years prior to first dose and no evidence of disease
  • Participants with concurrent malignancy clinically stable and not requiring tumor-directed treatment
• History of Coronavirus disease 2019 (COVID-19) infection within 4 weeks prior to enrollment and/or has persistent clinically significant pulmonary symptoms related to prior COVID-19 infection.

Other illness

• Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.
• Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment.
• Active bleeding disorders.
• Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class.

Lab values

• Has received any of the following within the specific time frame specified:
  • Participant has received Zipalertinib (TAS6417/CLN081) at any time
  • CNS radiotherapy (gamma knife radiotherapy is allowed) ≤ 12 weeks, thoracic radiotherapy ≤ 28 days, or other palliative radiation ≤ 14 days prior to the first dose of study
  • Anticancer immunotherapy ≤28 days prior to the first dose of study treatment
  • Major surgery (excluding placement of vascular access) ≤28 days prior to the first dose of study treatment.
  • Any prior treatment with an EGFR exon20ins- targeted TKI
  • Participants with leptomeningeal CNS disease.
• Impaired cardiac function or clinically significant cardiac disease including any of the following:
  • History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification.
  • Serious cardiac arrhythmias requiring treatment.
  • Resting corrected QT interval (QTc) \>470 msec using Fridericia's formula (QTcF).

Other

• Is pregnant, lactating, or planning to become pregnant.
• The participant is, in the Investigator's opinion, unable or unwilling to comply with the trial procedures.

• Written informed consent.
• ≥18 years of age (or meets the country's regulatory definition of legal adult age, whichever is greater.
• Pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:
  • Cohort A participants:
  • Documented EGFR ex20ins status, as determined by local testing performed at a Clinical Laboratory Improvement Amendments (CLIA) certified (United States \[US\]) or locally certified laboratory (outside the US).
  • Progressed on or after systemic therapy with an agent targeting ex20ins, either alone or in combination with standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.
  • Permitted prior ex20ins therapies include: amivantamab, sunvozertinib (DZD9008), and BLU451. Other prior ex20ins--directed treatment may be discussed with the Sponsor for eligibility assessment.
  • Participants with brain metastasis must be neurologically stable. Participants must have received central nervous system (CNS)-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging \[MRI\] or computed tomography \[CT\] scan) during the Screening Period. Additionally, they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with a history of uncontrolled seizures or LMD are not eligible.
  • Cohort B participants:
  • Documented EGFR ex20instatus, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US).
  • Participants who have not received prior treatment for advanced or metastatic disease and who are not appropriate candidates for first-line doublet platinum-based chemotherapy based on Investigator judgment or has refused first-line doublet platinum-based chemotherapy following discussion with the Investigator. Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed \>6 months prior to the first dose of study treatment.
  • Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible.
  • Cohort C participants:
  • Documented ex20ins or other uncommon single or compound EGFR non-ex20ins status, as determined by local testing performed at a CLIA-certified (US) or locally certified laboratory (outside the US).
  • Presence of brain metastasis(es) characterized as at least one of the following:
  • Newly diagnosed and/or progressive brain metastasis(es) measurable by Response Assessment in Neuro-oncology Brain Metastases (RANO-BM) criteria and not subjected to CNS-directed therapy, AND/OR
  • LMD measurable or non-measurable by RANO-BM criteria and confirmed by a positive cerebrospinal fluid cytology, or unequivocal radiographic and/or clinical determination.
  • Participants may not require other immediate CNS-directed therapy or will likely require other CNS directed anti-tumor therapy during the first cycle of study treatment, as judged by the Investigator.
  • Cohort D participants:
  • Documented other uncommon single or compound EGFR non-ex20ins status (excluding C797S), as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US). A list of eligible mutations will be provided in a separate document.
  • Participants with brain metastasis must be neurologically stable. Participants must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the Screening Period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Participants with history of uncontrolled seizures or LMD are not eligible.
  • Participants who have not received prior systemic therapy for their locally advanced or metastatic NSCLC disease.
  • Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed \>6 months prior to the first dose of study treatment. Participants may not have received prior adjuvant/neoadjuvant treatment with any EGFR tyrosine kinase inhibitor (TKI).
• Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
• Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers (details provided in a laboratory manual). Participants with insufficient tissue may be eligible following discussion with the Sponsor.
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 17.
• Adequate organ function, as defined by the hematologic, renal and hepatic laboratory values.
• Women of childbearing potential (WOCBP) must have a negative serum pregnancy test prior to administration of the first dose of study treatment. Female participants are not considered to be of childbearing potential if they are post-menopausal (no menses for 12 months without an alternative medical cause) or permanently sterile (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).
• Both males and females of reproductive potential must agree to use effective birth control during the study prior to the first dose of study drug and for 1 month after the last dose of study treatment.
  • DDI Substudy:
• Participant has pathologically confirmed, locally advanced or metastatic NSCLC:
  • Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendments (CLIA) certified (US) or locally certified laboratory (outside of the US) local laboratory, defined as either one of the following EGFRmts:
  • ex20ins EGFRmt OR
  • other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) OR
  • common EGFRmt (eg, ex19del or L858R)
• Participant has progressed on or after receiving prior standard of care (SoC) systemic therapy for their locally advanced or metastatic NSCLC disease unless:
  • Participant for whom no approved therapy with demonstrated clinical benefit is indicated or available,
  • Participant is intolerant to the available first-line (1L) SoC treatment options, OR
  • Participant has refused 1L SoC treatment options (after being appropriately informed of the treatment options, risks, and benefits).
• Participants with brain metastasis are eligible if they fulfill all of the criteria below:
  • Have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS- directed treatment, as ascertained by brain imaging (MRI or CT scan) during the Screening Period,
  • Are on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment,
  • Are neurologically stable with no history of uncontrolled seizures.
• ECOG PS of 0 or 1.
  • Dose Optimization Substudy:
• Has pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:
  • Documented EGFR ex20ins status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US)
  • Progressed on or after systemic therapy standard platinum-based chemotherapy for the treatment of advanced disease. Participants who discontinued previous treatment due to unacceptable toxicity are eligible.
  • Note: Progression on or after systemic therapy with amivantamab is permitted (eg, given as monotherapy or in combination with chemotherapy).
• Participants with CNS metastases are eligible if both of the following criteria are met:
  • Measurable lesions according to RANO-BM defined as a contrast-enhancing lesion that can be accurately measured in at least one dimension, with a minimum size of 10 millimeters (mm), or at least 5 mm if MRI slice thickness is ≤ 1.5 mm ii. Previously received definitive local treatment and have stable CNS disease (defined as being neurologically stable and off corticosteroid for at least 2 weeks prior to enrollment) OR Asymptomatic CNS metastases ≤ 2 cm in size if, in the opinion of the investigator, immediate definitive treatment is not indicated.
• Measurable disease per RECIST 1.1.
• Has archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers
• ECOG PS of 0 or 1.
• Has adequate organ function.